The expression of Fas and Fas ligand, and the effects of interferon in chronic liver diseases with hepatitis C virus

Hepatology Research

Volumn 24, Issue 4, 2002, Pages 327-337

  Yoneyama, Kazuo ^a   Goto, Takashi ^a   Miura, Kouichi ^a   Mikami, Ken Ichirou ^a   Ohshima, Shigetoshi ^a   Nakane, Kunio ^a   Lin, Jiun Guey ^a   Sugawara, Masashiro ^a   Nakamura, Norio ^b   Shirakawa, Kamon ^b   Komatsu, Masafumi ^c   Watanabe, Sumio ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MOCHIDA PHARMACEUTICAL CO   (Japan)

^c Akita City General Hospital   (Japan)

Author keywords

Apoptosis; Chronic hepatitis C; Fas; Fas ligand; Interferon therapy; Liver cirrhosis

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BETA INTERFERON; FAS ANTIGEN; FAS LIGAND; INTERFERON; MESSENGER RNA;

ADULT; ANTIGEN BINDING; APOPTOSIS; CHRONIC LIVER DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIGAND BINDING; LIVER CELL; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW;

EID: 0036915555     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(02)00137-7     Document Type: Article

References (48)

1. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-56.
2. Raff MC. Social controls on cell survival and cell death. Nature 1992;356:397-400.
3. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1977;88:347-54.
4. Thompson CB. Apotosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
5. Kerr JFR, Cooksley WGE, Searle J, et al. The nature of piecemeal necrosis in chronic active hepatitis. The Lancet 1979:827-8.
6. Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251-306.
7. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
8. Bossi G, Griffiths GM. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nature Med 1999;5:90-6.
9. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
10. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995;154:2706-13.
11. Papoff G, Cascino I, Eramo A, Strace G, Lynch DH, Ruberti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996;156:4622-30.
12. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nature Med 1996;2:317-22.
13. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777-83.
14. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
15. Hengartner MO. The biochemistry of apoptosis. Nature 2000;497:770-6.
16. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-7.
17. Sträter J, Wellisch I, Riedl S, et al. CD95 (APO-1/Fas)-mediated apoptosis in colon epithlial cells: a possible role in ulcerative colitis. Gastroenterology 1997;113:160-7.
18. Nishizaki K, Minatoguchi S, Seishima M, et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 1997;29:1214-20.
19. Hashimoto H, Tanaka M, Suda T, et al. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1998;41:657-62.
20. Kanda Y, Tanaka Y, Shirakawa K, et al. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant 1998;22:751-4.
21. Strand S, Hofmann W, Grambihler J, et al. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nature Med 1998;4:588-93.
22. Saito M, Nakamura N, Nagai M, et al. Increased levels of soluble Fas ligand in CSF of rapidly progressive HTLV-1-associated myelopathy/tropical spastic paraparesis patients. J Neuroimmunol 1999;98:221-6.
23. Kita H, Moriyama T, Kaneko K, et al. A helper T-cell antigen enhances generation of hepatitis C virus cytotoxic T lymphocytes in vitro. J Med Virol 1995;45:386-91.
24. Koziel MJ, Dudley D, Afdhal N, et al. HLA class1-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995;96:2311-21.
25. Shirai M, Arichi T, Nishioka M, et al. CTL responses of HLA-2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of human carrying HLA-2.1. J Immunol 1995;157:2733-42.
26. Kägi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30.
27. Vassalli P. The pathophysiology of tumor necrosis factors. Ann Rev Immunol 1992;10:411-52.
28. Sen GC, Lengye P. The Interferon system. A bird's eye view of its biochemistry. J Bio Chem 1992;267:5017-20.
29. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
30. Mochizuki K, Nakamura N, Hiramatsu N, et al. Fas antigen expression in liver tissue of patients with chronic hepatitis. B J Hepatol 1996;24:1-7.
31. Hiramatsu N, Nakamura N, Katayama K, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994;19:1354-9.
32. Galle PR, Hofmann WJ, Walczak H, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995;182:1223-30.
33. Iio S, Hayashi N, Mita E, et al. Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 1998;29:517-23.
34. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995;14:1129-35.
35. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nature Med 1998;4:31-6.
36. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995;83:793-802.
37. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000;191:1209-19.
38. Mita E, Hayashi N, Iio S, et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun. 1994;204:468-74.
39. Suzuki K, Endo R, Nakamura N, et al. Serum levels of soluble Fas ligand in patients with acute and fulminant hepatitis: relationship with soluble Fas, tumor necrosis factor α and TNF receptor-1. Hep Res 2000;17:19-30.
40. Anel A, Buferne N, Boyer C, Schmitt-Verhulst A-M, Golstein P. T-cell receptor induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. Eur J Immunol 1994;24:2469-76.
41. Sato K, Kimura F, Nakamura Y, et al. An agressive nasal lymphoma accompanied by high level of soluble Fas ligand. British J Hematol 1996;94:379-82.
42. Redondo C, Flores I, Gonzalez A, et al. Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes. J Clin Invest 1996;98:1245-52.
43. Tanaka N, Sato M, Lamphier MS, et al. Type I interferons are essential mediators of apoptotic death in virally infected cells. Genes Cells 1998;3:29-37.
44. Rice AP, Duncan R, Hershey JWB, Kerr IM. Double-stranded RNA-dependent protein kinase and 2-5AS system are both activated in interferon-treated, encephalomyocarditis virus-infected Hela cells. J Virol 1985;54:894-8.
45. Wathelet M, Moutschen S, Cravador A, et al. Full-length sequence and expression of the 42 kDa 2-5A synthetase induced by human interferon. FEBS Lett 1986;196:113-20.
46. Chebath J, Benech P, Revel M, Igneron M. Constitutive expression of (2′-5′) oligo A synthetase confers resistance to picornavirus interferon. Nature 1987;330:587-8.
47. Zilberstein A, Federman P, Shulman L, Revel M. Specific phosphorylation in vitro of a protein associated with ribosomes of interferon-treated mouse L cells. FEBS Lett 1976;68:119-24.
48. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti Fas antibody in mice. Nature 1993;364:806-9.